Tumor recurrence is common in patients with hepatitis C, hepatocellular carcinoma 

Understanding the Gut-Brain Connection May Give New Insights into Multiple Sclerosis
May 13, 2016
U.S. creating pink commemorative coin for breast cancer awareness
May 16, 2016
Show all

Tumor recurrence is common in patients with hepatitis C, hepatocellular carcinoma 

It’s not uncommon for liver cancer to come back even after treatment for hepatitis C with direct-acting antivirals was successful.

High rates of cancer recurrence are common in patients with hepatitis C and prior hepatocellular carcinoma who underwent treatment with direct-acting antivirals (DAA), according to research published in the Journal of Hepatology.

María Reig, MD, of the Barcelona Clinic Liver Cancer Group, and colleagues conducted a study of 103 patients with hepatitis C and a prior history of treated hepatocellular carcinoma; the patients had previously achieved complete response and lacked non-characterized nodules at the time of treatment with all-oral DAAs.

Fifty-eight patients met the study’s inclusion criteria. The researchers conducted a median follow-up of 5.7 months, in which 3 patients died and 16 patients (27.6%) developed a radiologic tumor recurrence. Of those 16 patients, 3 developed an intrahepatic growth. New intrahepatic lesions were found in 5 patients (1 nodule), 4 of whom developed up to 3 nodules less than or equal to 3 cm and one of whom developed a multifocal nodule. Three patients developed an infiltrative ill-defined hepatocellular carcinoma.

Read Full Article: Tumor recurrence is common in patients with hepatitis C, hepatocellular carcinoma – The Clinical Advisor

Read Full Article: Tumor recurrence is common in patients with hepatitis C, hepatocellular carcinoma – The Clinical Advisor

The health and medical information on our website is not intended to take the place of advice or treatment from health care professionals. It is also not intended to substitute for the users’ relationships with their own health care/pharmaceutical providers.

Comments are closed.